BIOMAT Database Logo BIOMAT Database Logo

Tumor necrosis factor in human monocyte-mediated antitumor cytotoxicity. 1988

H W Ziegler-Heitbrock, and C Thiel, and J G Haas, and A Möller, and G Riethmüller
Institute of Immunology, University of Munich, FRG.

The WEHI-164 target cells pretreated with actinomycin D can be employed in a 7-hour 51Cr release assay that exhibits exquisite susceptibility for cytotoxic monocytes without contribution by natural killer cells. The system can be used either to detect cell-mediated monocyte cytotoxicity directly or to measure cytotoxic-factor activity in cell-free supernatants. Analysis of cytotoxic factor demonstrates molecular characteristics similar to tumor necrosis factor (TNF), and polyclonal as well as monoclonal antibodies specific for TNF can readily neutralize the monocyte-generated cytotoxic factor. In the cell-mediated approach, neutralization can be achieved as well, although somewhat higher amounts of antibody are required. Hence, the WEHT-164/actinomycin D system appears to detect monocyte cytotoxicity that is mediated by TNF.

UI MeSH Term Description Entries
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

H W Ziegler-Heitbrock, and C Thiel, and J G Haas, and A Möller, and G Riethmüller
Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity.
November 1986, Cancer research,
H W Ziegler-Heitbrock, and C Thiel, and J G Haas, and A Möller, and G Riethmüller
Comparison of recombinant tumor necrosis factor and the monocyte-derived cytotoxic factor involved in monocyte-mediated cytotoxicity.
May 1987, Cancer research,
H W Ziegler-Heitbrock, and C Thiel, and J G Haas, and A Möller, and G Riethmüller
Role of tumor necrosis factor in monocyte/macrophage tumor cytotoxicity in vitro.
January 1987, Natural immunity and cell growth regulation,
H W Ziegler-Heitbrock, and C Thiel, and J G Haas, and A Möller, and G Riethmüller
Involvement of tumor necrosis factor in cytotoxicity mediated by human monocytes.
January 1988, Natural immunity and cell growth regulation,
H W Ziegler-Heitbrock, and C Thiel, and J G Haas, and A Möller, and G Riethmüller
Tumor necrosis factor-induced necrosis: a monocyte-mediated hypercoagulable effect.
July 1995, Journal of the National Medical Association,
H W Ziegler-Heitbrock, and C Thiel, and J G Haas, and A Möller, and G Riethmüller
Tumor necrosis factor-mediated cytotoxicity by tumor-associated macrophages.
October 1989, Cellular immunology,
H W Ziegler-Heitbrock, and C Thiel, and J G Haas, and A Möller, and G Riethmüller
Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism.
March 1988, Blood,
H W Ziegler-Heitbrock, and C Thiel, and J G Haas, and A Möller, and G Riethmüller
Hyperthermic modulation of tumor necrosis factor-dependent monocyte/macrophage tumor cytotoxicity in vitro.
June 1989, Journal of biological response modifiers,
H W Ziegler-Heitbrock, and C Thiel, and J G Haas, and A Möller, and G Riethmüller
Effector mechanism of human monocyte-mediated cytotoxicity: role of a new tumor cytotoxic factor distinct from interleukin 1 and tumor necrosis factor alpha.
January 1989, Biotherapy (Dordrecht, Netherlands),
H W Ziegler-Heitbrock, and C Thiel, and J G Haas, and A Möller, and G Riethmüller
Tumor necrosis factor-mediated cytotoxicity involves ADP-ribosylation.
June 1988, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!